comprehensive -WSS

comprehensive

author：knowledge 2025-09-27 09:45:02 - browse：81

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Monday approved a gene therapy for metachromatic leukodystrophy, a devastating genetic disorder that eats away at affected children’s neurons.

The medicine, marketed as Lenmeldy, is the first treatment for MLD, which is otherwise fatal. Lenmeldy has to be given before symptoms appear or, in some cases, after the first signs of disease, so it won’t be helpful for many patients living with MLD today. But when given in time, it appears to be near-curative, allowing some children to grow up and attend school with unaffected peers.

Lenmeldy is already marketed in Europe, under the name Libmeldy, and has helped a handful of patients in the U.S. who were treated under compassionate use, as their doctors feared they didn’t have time to wait for approval.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： States should stop sabotaging methadone treatment reform

hotspot

WSS

What affirmative action's end means to a medical student

There's no autism epidemic. It's an autism diagnosis epidemic

Skip the lead apron during X

FDA's naming rule on biosimilars has undermined competition

Vertex Pharmaceuticals may move headquarters in Boston

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

hotspot

comprehensive

knowledge

Walensky prepares to leave CDC — and Congress — behind

Steward Health Care has deal to sell doctor network to UnitedHealth

DIEP, the 'gold standard' of breast reconstruction, is under threat

Patient advocates debate FDA's accelerated approval process

Wildfire smoke exposes gaps in outdoor worker protections

Oprah kicked off a national conversation on obesity. Let's have it

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Crowdfunding for unproven stem cell procedures spreads misinformation

New air purifier tech could be key to improving indoor air quality

Donor acceptance rates hint at racial, gender bias in heart transplants: study

focus

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Vertex Pharmaceuticals may move headquarters in Boston

'Screen and refer' systems are hurting patients

Drug cartel violence flares in western Mexico after vigilante leader's killing

What affirmative action's end means to a medical student

focus

hotspot

hotspot

hotspot